3 Key Takeaways
Plain English Summary- 01Core Finding
Here we created a single-cell atlas to define how ILC3s respond to distinct stimuli, observing that prostaglandin engages protein kinase A (PKA) to upregulate tissue-protective factors.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
What This Means for You
Overproduction of IL-23 was sufficient to reduce PRKAR1A in ILC3s and increase PKA signaling that provoked gut inflammation. Finally, ILC3s from the healthy human intestine expressed PRKAR1A, which was downregulated by IL-23 or in inflammatory bowel disease. These results demonstrate that regulated PKA signaling is essential for tissue-protective ILC3s, while IL-23 drives aberrant PKA signaling to elicit intestinal inflammation.
The Discovery
Group 3 innate lymphoid cells (ILC3s) are tissue-protective lymphocytes that are enriched in the healthy gut and depleted in gastrointestinal disorders. Here we created a single-cell atlas to define how ILC3s respond to distinct stimuli, observing that prostaglandin engages protein kinase A (PKA) to upregulate tissue-protective factors. In contrast, the canonical activator interleukin-23 (IL-23) decreased negative regulators of PKA, including PRKAR1A. Lineage-specific Prkar1a deletion reduced ILC3s and increased susceptibility to enteric infection in mice. PRKAR1A was not required in early life but continuously preserved ILC3 homeostasis in adults by restraining PKA activity.
How It Works, Simply
This immunology research focuses on inflammation. Researchers evaluated it using an in vivo animal model (Preclinical discovery) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Here we created a single-cell atlas to define how ILC3s respond to distinct stimuli, observing that prostaglandin engages protein kinase A (PKA) to upregulate tissue-protective factors.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models
In vivo animal model (Preclinical discovery) · Preclinical
Biological Pathway & Modality
Inflammation
Intervention: PKA signaling controls ILC3 homeostasis and IL-23-mediated inflammation in the gut
Experimental Findings & Endpoints
Group 3 innate lymphoid cells (ILC3s) are tissue-protective lymphocytes that are enriched in the healthy gut and depleted in gastrointestinal disorders.
Here we created a single-cell atlas to define how ILC3s respond to distinct stimuli, observing that prostaglandin engages protein kinase A (PKA) to upregulate tissue-protective factors. In contrast, the canonical activator interleukin-23 (IL-23) decreased negative regulators of PKA, including PRKAR1A.
Lineage-specific Prkar1a deletion reduced ILC3s and increased susceptibility to enteric infection in mice. PRKAR1A was not required in early life but continuously preserved ILC3 homeostasis in adults by restraining PKA activity.
Clinical Translation & Practice Context
Overproduction of IL-23 was sufficient to reduce PRKAR1A in ILC3s and increase PKA signaling that provoked gut inflammation.
Finally, ILC3s from the healthy human intestine expressed PRKAR1A, which was downregulated by IL-23 or in inflammatory bowel disease. These results demonstrate that regulated PKA signaling is essential for tissue-protective ILC3s, while IL-23 drives aberrant PKA signaling to elicit intestinal inflammation.
The Bottom Line · Clinical Pearl
“These results demonstrate that regulated PKA signaling is essential for tissue-protective ILC3s, while IL-23 drives aberrant PKA signaling to elicit intestinal inflammation.”
Published in Nature Immunology · Current Stage: Preclinical
